Trevi Therapeutics (NASDAQ:TRVI) Stock Rating Upgraded by Raymond James
Trevi Therapeutics (NASDAQ:TRVI – Get Free Report) was upgraded by Raymond James from an “outperform” rating to a “strong-buy” rating in a research note issued to investors on Monday, Marketbeat Ratings reports. The brokerage currently has a $29.00 target price on the stock, up from their prior target price of $9.00. Raymond James’ target price […]
Trevi Therapeutics (NASDAQ:TRVI – Get Free Report) was upgraded by Raymond James from an “outperform” rating to a “strong-buy” rating in a research note issued to investors on Monday, Marketbeat Ratings reports. The brokerage currently has a $29.00 target price on the stock, up from their prior target price of $9.00. Raymond James’ target price […]
